Lupus Erythematosus in Senegal: Study of 340 Cases

Diallo M*, Diatta BA, Diop A, Ndiaye MT, Ndiaye M, Seck B, Deh A, Diop K, Ly F and Niang SO

Department of Dermatology, Aristide LeDantec University Hospital, Dakar, Senegal

Abstract

Introduction: In Africa, an increase in the incidence of lupus erythematosus has been noted in recent years. Very few studies have been conducted on epidemiological and clinical aspects of this disease in sub-Saharan Africa. The purpose of this study was to report the epidemiological, clinical and evolutionary aspects of lupus disease in an African Black population.

Materials and methods: This was a retrospective cross-sectional study including all cases of lupus seen in two departments of Dermatology in Dakar from 1999 to 2015.

Results: Three hundred and forty cases were recorded, corresponding to a hospital frequency of 0.05%. The average age was 33 years. The sex ratio was 0.17. The various manifestations were: dermatological (89.4%), rheumatological (33.2%), cardiac (5.8%), renal (12%), respiratory (5.6%), neuropsychiatric (4.7%), digestive (2.6%), hematological (70%) and immunological (56.2%). Lupus was associated with antiphospholipid antibody syndrome (35%), dermatomyositis (26.3%), rheumatoid arthritis (17.5%) and scleroderma (21%). Patients were treated with corticosteroids (92%), immunosuppressive (12%) and synthetic antimalarial drugs (88.2%). A remission was noted in 80%. The complications were an infection (20.5%) and the occurrence of squamous cell carcinoma (0.8%). Death occurred in 2.6%.

Conclusion: Lupus erythematosus is a frequent condition in our regions and represents the first connective tissue disease in our department. Systemic lupus erythematosus is by far the most frequent form, followed by chronic lupus, while subacute lupus seems very rare. The disease is often severe with frequent visceral involvements. The prognosis is still poor in our regions due to the delayed diagnosis with frequent renal involvement and frequent infectious complications.

Keywords: Lupus erythematosus; Epidemiological aspects; Evolutionary aspects; Clinical aspects

Introduction

In Africa, an increase in the incidence of lupus erythematosus has been noted in recent years [1-3]. A higher severity of the disease has also been postulated in African population [2,4]. However, most of these assertions are based on studies conducted in Western countries, especially in African-American population [1,2,4]. Very few studies have been conducted on epidemiological and clinical aspects of this disease in sub-Saharan Africa [3-7]. The purpose of this study was to report the epidemiological, clinical and evolutionary aspects of lupus disease in an African black population.

Materials and Methodology

This was a retrospective cross-sectional study including all cases of lupus erythematosus seen in two departments of Dermatology of Dakar from 1999 to 2015. The medical records of patients meeting the diagnostic criteria of the American College of Rheumatology were reviewed. The data was collected and analysed using Sphinx Demo and SPSS 13.0 software.

Results

We collected 340 patients with lupus erythematosus corresponding to a hospital frequency of 0.05%. Lupus represented the first connective tissue disease in our departments. The mean age was 33 years (5-70 years), with a sex ratio of 0.17 (290 women-50 men). The average duration before consultation was 24 months (3 days-20 years). Skin lesions were inaugural in 89.4% (n=304). Opportunistic superficial fungal infections were the circumstances of discovery in 33% (n=112). Clinical forms were a systemic acute lupus erythematosus in 80% (n=272), a chronic discoid lupus in 15.6% (n=53) and a subacute lupus in 4.4% (n=15). In patients with acute systemic lupus, elementary lesions were acute in 40% (n=109),

subacute in 8.8% (n=24), chronic in 26% (n=71) and combined in the same patient in 25% (n=68). Acute lesions consisted of specific signs (erythema on malar region, ears or trunk and mucosal erosions) and non-specific manifestations (purpura, Raynaud’s syndrome, alopecia and bullae) (Figure 1).

The different types of acute lupus lesions are shown in Table 1. In chronic lupus (Figure 2), the primary lesions were discoid in 50.9% (n=27), verrucocous variant in 3.8% (n=2), vitiligoide in 28.3% (n=15)

Keywords: Lupus erythematosus; Epidemiological aspects; Evolutionary aspects; Clinical aspects

Introduction

In Africa, an increase in the incidence of lupus erythematosus has been noted in recent years [1-3]. A higher severity of the disease has also been postulated in African population [2,4]. However, most of these assertions are based on studies conducted in Western countries, especially in African-American population [1,2,4]. Very few studies have been conducted on epidemiological and clinical aspects of this disease in sub-Saharan Africa [3-7]. The purpose of this study was to report the epidemiological, clinical and evolutionary aspects of lupus disease in an African black population.

Materials and Methodology

This was a retrospective cross-sectional study including all cases of lupus erythematosus seen in two departments of Dermatology of Dakar from 1999 to 2015. The medical records of patients meeting the diagnostic criteria of the American College of Rheumatology were reviewed. The data was collected and analysed using Sphinx Demo and SPSS 13.0 software.

Results

We collected 340 patients with lupus erythematosus corresponding to a hospital frequency of 0.05%. Lupus represented the first connective tissue disease in our departments. The mean age was 33 years (5-70 years), with a sex ratio of 0.17 (290 women-50 men). The average duration before consultation was 24 months (3 days-20 years). Skin lesions were inaugural in 89.4% (n=304). Opportunistic superficial fungal infections were the circumstances of discovery in 33% (n=112). Clinical forms were a systemic acute lupus erythematosus in 80% (n=272), a chronic discoid lupus in 15.6% (n=53) and a subacute lupus in 4.4% (n=15). In patients with acute systemic lupus, elementary lesions were acute in 40% (n=109),

subacute in 8.8% (n=24), chronic in 26% (n=71) and combined in the same patient in 25% (n=68). Acute lesions consisted of specific signs (erythema on malar region, ears or trunk and mucosal erosions) and non-specific manifestations (purpura, Raynaud’s syndrome, alopecia and bullae) (Figure 1).

The different types of acute lupus lesions are shown in Table 1. In chronic lupus (Figure 2), the primary lesions were discoid in 50.9% (n=27), verrucocous variant in 3.8% (n=2), vitiligoide in 28.3% (n=15)

*Corresponding author: Dr. Moussa Diallo, Department of Dermatology, Aristide LeDantec University Hospital, Dakar, Dakar-Etoile, Senegal, Tel: 00 (221) 77 762 90 90; E-mail: moussante@hotmail.com

Received: October 12, 2017; Accepted: November 28, 2017; Published: December 12, 2017

Citation: Diallo M, Diatta BA, Diop A, Ndiaye MT, Ndiaye M, et al. (2017) Lupus Erythematosus in Senegal: Study of 340 Cases. Dermatol Case Rep 2: 135.

Copyright: © 2017 Diallo M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
and lupus panniculitis in 16.9% (n=9). The discoid lesions were found on the face in 2 cases, limbs and trunk in 14 cases and on the scalp with scarring alopecia in 11 cases. In subacute lupus, lesions were erythematous annular in 5 cases and psoriasiform in 10 patients (Figure 3). Extra-cutaneous manifestations were rheumatological in 33.2% (n=113), cardiac in 5.8% (n=20), renal in 12% (n=41), respiratory in 5.6% (n=19), neurospsychic in 4.7% (n=16), digestive in 2.6% (n=9), hematological in 70% (n=238) and immunological in 56.2% (n=191) (Table 2). Systemic lupus was associated with other autoimmune disease in 16.7% (n=57). This was anti-phospholipid syndrome (APS) in 35% (n=20), dermatomyositis in 26.3% (n=15), rheumatoid arthritis in 17.5% (n=10) and scleroderma in 21% (n=12). Oral corticosteroid therapy (prednisone) was used in 92% (n=313). Other treatments were immunosuppressive (cyclophosphamide, azathioprine) in 12% (n=41) and synthetic antimalarials in 88.2% (n=300).

The average follow-up period was 24 months (7 days to 18 years). Clinical remission was noted in 80% (n=272) and 33.2% (n=113) were lost to follow-up. Complications during treatment are listed in Table 3. Squamous cell carcinoma secondary to discoid lupus lesion was noted in 3 cases (Figure 4). Death occurred in 2.6% (n=9) was secondary to severe infections and renal involvements.

Discussion

We reported one of the largest series of lupus erythematosus in sub-Saharan Africa [3-7] (Table 4). Lupus is a frequent condition in our region and represents the first connective tissue disease in our department. This high frequency has been well reported in the African population and may be related to the great sun-exposure [1,2]. The disease seems to occur earlier in life in this population as evidenced by
Table 4: Comparison of epidemiological, clinical and evolutionary aspects of lupus erythematosus in different African series.

| Aspects                  | Our study (Senegal) | Iba (6) (Gabon) | Daboiko (7) (Ivory Coast) | Bija (7) (Camerone) | Khanfir (10) (Tunisia) |
|--------------------------|---------------------|-----------------|--------------------------|--------------------|------------------------|
| **Epidemiology**         |                     |                 |                          |                    |                        |
| Number of cases          | 340                 | 37              | 49                       | 39                 | 781                    |
| Hospital prevalence (%)  | 0.05                | 0.14            | 0.4                      | 0.4                | -                      |
| Mean age (years)         | 33                  | 32              | 35                       | 39.2               | 30                     |
| Sex-ratio                | 0.17                | 0.06            | 0.04                     | 0.08               | 0.15                   |
| Diagnostic delay         | 24                  | 17              | 13                       | 15                 | 15                     |
| **Clinical, n (%)**      |                     |                 |                          |                    |                        |
| Dermatological           | 340 (100)           | 23 (62.2)       | 29 (59.2)                | 22 (55.4)          | 612 (81.7)             |
| Rheumatologic            | 113 (33.2)          | 22 (59.4)       | 38 (77.5)                | 25 (64.1)          | 512 (24.8)             |
| Cardiac                  | 20 (5.9)            | 6 (16.2)        | 13 (26.5)                | -                  | 239 (31.9)             |
| Respiratory              | 19 (5.6)            | 5 (13.5)        | 9 (18.4)                 | -                  | 194 (26)               |
| Renal                    | 16 (4.7)            | 6 (16.2)        | 24 (49)                  | 7 (17.9)           | 371 (49.5)             |
| Neurosychiatric          | 16 (4.7)            | 9 (24.3)        | 11 (22.4)                | 4 (10.3)           | 35 (4.7)               |
| Lymphadenopathy          | 6 (1.8)             | 6 (16.2)        | -                        | -                  | -                      |
| **Evolution, n (%)**     |                     |                 |                          |                    |                        |
| Remission                | 272 (80)            | 31 (83.7)       | 29 (50.2)                | 27 (69.2)          | 258 (33.8)             |
| Relapse                  | 30 (8.8)            | -               | 5 (12.8)                 | -                  | -                      |
| Infections               | 70 (20.5)           | -               | 27 (55.1)                | 2(5.2)             | 355 (45.5)             |
| Carcinoma                | 3 (0.8)             | -               | -                        | -                  | -                      |
| Death                    | 9 (2.6)             | 2 (5.4)         | 11 (22.4)                | 2 (5.2)            | 56 (7.2)               |
| Loss of follow-up        | 113 (33)            | 6 (16.2)        | 20 (40.8)                | -                  | -                      |

Table 4: Squamous cell carcinoma occurred on discoid lesions of the lower lip.

the young age of our patients. We also find an increase in the incidence of lupus compared to previous studies in the same departments [3,4]. The increase in its frequency may be related to an improvement in the diagnosis and a better access of the population to consultants in Dermatology. Despite this, there is still an important delay for the diagnosis which is about 24 months and seems to be related to the chronicity of the condition.

Lupus erythematosus is a frequent condition in our region where it represents the first connective tissue disease. The diagnosis is often delayed. The condition is usually severe with a clear predominance of systemic forms. Furthermore, there are several forms of systemic lupus often associated with visceral and infectious complications. In contrast, subacute lupus erythematosus seems very rare in this population. In chronic lupus, transformation of discoid lesions into squamous cell carcinoma can occur. The prognosis is still poor due to the delayed diagnosis, the frequent discontinuation of treatments and loss of follow up, favored by the chronicity of the condition.

Conflict of Interests
None

References
1. Saraux A, Jousse S, Roudaut A, Devauchelle V (2005) Épidémiologie du lupus érythémateux systémique. Rev Rhum 72: 117-119.
2. Olivier M (2002) Lupus systémique chez les non-Caucasiens. Rhum 69:801-808.
3. Ka MM, Diallo S, Kane A, Wade B, Diouf B, et al. (1998) Systemic lupus erythematosus and lupus syndromes in Senegal. A retrospective study of 30 patients seen over 10 years. Rev Rhum Engl Ed 65: 471-476.
4. Diop MM, Gueye YA, Léye A, Touré PS, Berthe A, et al. (2014) The ways of presentation, treatment and outcome of patients with systemic lupus erythematosus seen at a rheumatology clinic in Douala, Cameroon. Health Sci Dis 15: 1-5.
5. Bija MD, Luma NH, Ashuntantang G, Epée H, Kemta F, et al. (2014) Clinical presentation, treatment and outcome of patients with systemic lupus erythematosus seen at a rheumatology clinic in Douala, Cameroon. Health Sci Dis 15: 1-5.
6. Iba BA, Nzenzer JB, Bitezhe B, Missounga L, Bignoumba IR, et al. (2011) Clinical, Biological and Evolutionary Profile of Systemic Lupus in a Hospital in Libreville. Med Afr Noire 58: 551-559.
7. Daboiko JC, Gueret M, Etie E (2004) Clinical and progressive profile of systemic lupus erythematosus in Abidjan: About 49 cases collected at Cocomy CHU. Med Afr noire 51:144-146.
8. Jalilou M, Frigui M, Marzouka S, Maalouf I, Kaddour N, et al. (2008) Infectious complications in systemic lupus erythematosus: study of 146 patients. Rev Med Interne 29: 626-631.
9. Ndiaye B, Develoux M, Dieng MT, Ndir O (1995) Fréquence des teignes chez les patients atteints de connectivités à Dakar (Sénégal). Journal de Mycologie médicale 5: 239-243.

10. Khanfir MS, Hournan MH, Cherif E, Hamzzaoui A, Souissi S, et al. (2013) TULUP (Tunisian Lupus): A multicentric study of systemic lupus erythematosus in Tunisia. Int J Rheum Dis 16: 539-546.

11. Ka EF, Ciase MM, Lemrabott AT, Diallo S, Faye M, et al. (2013) Néphropathie lupique chez les sujets génétiquement pigmentés vivant au Sénégal: à propos de quarante-trois cas. Med Sante Trop 23: 329-331.

12. Dieng MT, Ndiaye A (2001) Carcinome épidermoide sur Lupus érythémateux discoïde (Trois Observations). Dakar Méd 46 :73-75.